Cogent Biosciences, Inc. Interest Expense Nonoperating
Cogent Biosciences, Inc. (COGT) reported Interest Expense Nonoperating of $1.22 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement
us-gaap:InterestExpenseNonoperating · last filed 2026-08-10
- Cogent Biosciences, Inc. interest expense nonoperating for the quarter ending 2026-06-30 was $1.22M, a 287.58% increase year-over-year.
- Cogent Biosciences, Inc. interest expense nonoperating for the quarter ending 2026-03-31 was $1.21M.
- Cogent Biosciences, Inc. interest expense nonoperating for the quarter ending 2025-12-31 was $1.29M.
- Cogent Biosciences, Inc. interest expense nonoperating for the quarter ending 2025-09-30 was $1.46M.
- Cogent Biosciences, Inc. interest expense nonoperating for fiscal 2025 was $3.06M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.22M 10-Q · filed 2026-08-10 | $2.43M 10-Q · filed 2026-08-10 | $3.72M derived: sum of 3 quarters · filed 2026-08-10 | $5.18M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $1.21M 10-Q · filed 2026-05-05 | $2.50M derived: sum of 2 quarters · filed 2026-05-05 | $3.96M derived: sum of 3 quarters · filed 2026-05-05 | $4.28M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $1.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $2.75M derived: sum of 2 quarters · filed 2026-02-17 | $3.06M derived: sum of 3 quarters · filed 2026-08-10 | $3.06M 10-K · filed 2026-02-17 |
| 2025-09-30 | $1.46M 10-Q · filed 2025-11-07 | $1.77M derived: sum of 2 quarters · filed 2026-08-10 | $1.77M 10-Q · filed 2025-11-07 | |
| 2025-06-30 | $314.00K 10-Q · filed 2026-08-10 | $314.00K 10-Q · filed 2026-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |